261 related articles for article (PubMed ID: 32206098)
1. Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity.
Sethuraman SN; Singh MP; Patil G; Li S; Fiering S; Hoopes PJ; Guha C; Malayer J; Ranjan A
Theranostics; 2020; 10(8):3397-3412. PubMed ID: 32206098
[No Abstract] [Full Text] [Related]
2. The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy.
Zhang Y; Akhil V; Seo HS; Park HR; Kim SH; You SH; Liu Z; Kim SY; Sultonova RD; Min JJ; Hong Y
Theranostics; 2024; 14(3):1195-1211. PubMed ID: 38323311
[TBL] [Abstract][Full Text] [Related]
3. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
4. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death.
Duan XC; Peng LY; Yao X; Xu MQ; Li H; Zhang SQ; Li ZY; Wang JR; Feng ZH; Wang GX; Liao A; Chen Y; Zhang X
Drug Deliv; 2021 Dec; 28(1):800-813. PubMed ID: 33866918
[TBL] [Abstract][Full Text] [Related]
5. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
[No Abstract] [Full Text] [Related]
6. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
7. Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.
Maines LW; Keller SN; Smith CD
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069222
[TBL] [Abstract][Full Text] [Related]
8. ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death.
Zhang Y; Guo C; Liu L; Xu J; Jiang H; Li D; Lan J; Li J; Yang J; Tu Q; Sun X; Alamgir M; Chen X; Shen G; Zhu J; Tao J
Theranostics; 2020; 10(24):11197-11214. PubMed ID: 33042278
[No Abstract] [Full Text] [Related]
9. PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
Tang X; Rao J; Yin S; Wei J; Xia C; Li M; Mei L; Zhang Z; He Q
Eur J Pharm Sci; 2019 Jan; 127():161-174. PubMed ID: 30366077
[TBL] [Abstract][Full Text] [Related]
10. In-situ vaccination using focused ultrasound heating and anti-CD-40 agonistic antibody enhances T-cell mediated local and abscopal effects in murine melanoma.
Singh MP; Sethuraman SN; Ritchey J; Fiering S; Guha C; Malayer J; Ranjan A
Int J Hyperthermia; 2019 Nov; 36(sup1):64-73. PubMed ID: 31795832
[TBL] [Abstract][Full Text] [Related]
11. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
12. Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Effective Modality to Enhance Anti-Tumor Immune Response by Inducing Immunogenic Cell Death in Breast Cancer.
Si Y; Yue J; Liu Z; Li M; Du F; Wang X; Dai Z; Hu N; Ju J; Gao S; Wang X; Yuan P
Int J Nanomedicine; 2021; 16():1913-1926. PubMed ID: 33707946
[TBL] [Abstract][Full Text] [Related]
13. Melanoma B16-F1 cells coated with fusion protein of mouse calreticulin and virus G-protein coupled receptor induced the antitumor immune response in Balb/C mice.
Qin Y; Han Y; Cao C; Ren Y; Li C; Wang Y
Cancer Biol Ther; 2011 Mar; 11(6):574-80. PubMed ID: 21270533
[TBL] [Abstract][Full Text] [Related]
14. Evidence of immunogenic cancer cell death induced by honey-processed Astragalus polysaccharides in vitro and in vivo.
Sha X; Xu X; Liao S; Chen H; Rui W
Exp Cell Res; 2022 Jan; 410(1):112948. PubMed ID: 34826423
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
16. Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla G; Radecke C; Frentsch M; Walther W; Stintzing S; Riess H; Bullinger L; Na IK
Oncoimmunology; 2022; 11(1):2068109. PubMed ID: 35496500
[TBL] [Abstract][Full Text] [Related]
17. Age-associated changes in the gut microbiome impact efficacy of tumor immunomodulatory treatments.
Singh A; Ashar H; Butcher JT; Ranjan A
Exp Gerontol; 2023 Oct; 181():112268. PubMed ID: 37572993
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Resistance to Immune Checkpoint Inhibitor Therapy Using Calreticulin-Inducing Nanoparticle.
Chandrasekar SV; Singh A; Ranjan A
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376141
[TBL] [Abstract][Full Text] [Related]
19. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
20. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
